Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N -demethylation in human liver microsomes

Reference

• BECQUEMONT, L., MOUAJJAH, S., ESCAFFRE, 0., BEAUNE, P., FUriCk-BRENTANO, C. and JAILLON, P., 1999, Cytochrome P-450 3A4 and 2C8 are involved in Zopiclone metabolism. Drug Metabolism and Disposition, 27, 1068–1073.
   Google Scholar
• BRUNK, F. and DELLE, M., 1974, Morphine metabolism in man. Clinical Pharmacology and Therapeutics, 16, 51–57.
   PubMed Web of Science ®Google Scholar
• CARACO, Y., TATEISHI, T., GUENGERICH, F. P. and WOOD, A. J. J., 1996, Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metabolism and Disposition, 24, 761–764.
   PubMed Web of Science ®Google Scholar
• CARLILE, D. J., ZOMORODI, K. and HOUSTON, J. B., 1997, Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metabolism and Disposition, 25, 903–911.
   PubMed Web of Science ®Google Scholar
• CLARKE, S. E., 1998, In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167-1202. COFFMAN, B. L., Rios, G. R., KING, C. D. and TEPHLY, T. R., 1997, Human UGT2B7 catalyses morphine glucuronidation. Drug Metabolism and Disposition, 25, 1–4.
   Google Scholar
• CRESPI, C. L. and MILLER, V. P., 1999, The use of heterologously expressed enzymes— state of the art and prospects for the future. Pharmacology and Therapeutics, 84, 121–131.
   PubMed Web of Science ®Google Scholar
• FAURA, C. C., MOORE, A., HORGA, J. F., HAND, C. W. and McQuAY, H. J., 1996, Morphine and morphine-6-glucuronide and effect in cancer pain. Journal of Pain Symptoms and Management, 11, 95–102.
   PubMed Web of Science ®Google Scholar
• FELBY, S., CHRISTENSEN, H. and LUND, A., 1974, Morphine concentration in blood and organs in cases of fatal poisoning. Forensic Science, 3, 77–81.
   PubMedGoogle Scholar
• FRomm, M. F., ECKHARDT, K., LI, S., SCHANZLE, G., HOFMANN, U., MIKUS, G. and EICHELBAU M., 1997, Loss of analgesic effect of morphine due to coadministration of rifampin. Pain, 72, 261–267.
   PubMed Web of Science ®Google Scholar
• GLARE, P. A. and WALSH, T. D., 1991, Clinical pharmacokinetics of morphine Therapeutic Drug Monitoring, 335, 1–23.
   Google Scholar
• GLARE, P. A., WALSH, T. D. and PIPPENGER, C. E., 1990, NORMORPHINE, a neurotoxic metabolite? Lancet, 335, 725–726.
   Google Scholar
• GREEN, M. D., KING, C. D., MOJARRABI, B., MaCKENZIE, P. I. and TEPHLY, T. R., 1998, Glucuronidation of amines and other xenobiotics catalysed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metabolism and Disposition, 26, 507–512.
   PubMed Web of Science ®Google Scholar
• Hasselström, J. and Sawe, J., 1993, Morphine pharmacokinetics and metabolism in human. Clinical Pharmacokinetic, 24, 344–354.
   Google Scholar
• HOUSTON, J. B. and KENWORTHY, K. E., 2000, In vitro—in vivo scaling of CYP kinetic data not consistent with the classical Michaelis—Menten model. Drug Metabolism and Disposition, 28, 246–254.
   PubMed Web of Science ®Google Scholar
• INouE, K., YAMAZAKI, H., ImIYA, K., AKASAKA, S., GUENGERICH, F. P. and SHIMADA, T., 1997, Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4 -hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103–113.
   PubMedGoogle Scholar
• KERR, B. M., THUMMEL, K. E., WURDEN, C. J., KLEIN, S. M., KROETZ, D. L., GONZALES, F. J. and LEVY, R. H., 1994, Human carbamazepine metabolism—role of CYP3A4 and CYP2C8 in 10,11 epoxide formation. Biochemical Pharmacology, 47, 1969–1979.
   Web of Science ®Google Scholar
• KIRKWOOD, L. C., NATION, R. L. and SomoGYI, A. A., 1997, Characterization of the human cytochrome P450 enzyme involved in the metabolism of dihydrocodeine. British Journal of Clinical Pharmacology, 44, 549–555.
   PubMed Web of Science ®Google Scholar
• LASAGNA, L. and DE KORNFELD, T. J., 1958, Analgesic potency of normorphine in patients with postoperative pain. Journal of Pharmacology, 124, 260–263.
   Google Scholar
• LEVY, M. H., 1996, Drug therapy: pharmacologic treatment of cancer pain. New England Journal of Medicine, 335, 1124–1132.
   PubMed Web of Science ®Google Scholar
• LOFT, S., OTTON, V., LENNARD, M., TUCHER, G. and POULSEN, H., 1991, Characterisation of metronidazole metabolism by human liver microsomes. Biochemical Pharmacology, 41, 1127–1134.
   PubMed Web of Science ®Google Scholar
• MANCY, A., DIJOLS, S., POLI, S., GUENGERICH, F. P. and MANSUY, D., 1996, Interaction of sulphaphenazole derivatives with liver cytochrome P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9. Biochemistry, 35, 16205–16212.
   PubMed Web of Science ®Google Scholar
• MASIMIREMBWA, C. M., OTTER, C., BERG, M., JONSSON, M., LEIDVIK, B., JONSSON, E., JOHANSSON, T., BACKMAN, A., EDLUND, A. and ANDERSSON, T. B., 1999, Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metabolism and Disposition, 27, 1117–1122.
   PubMed Web of Science ®Google Scholar
• MILNE, R. W., NATION, R. L. and SomoGYI, A. A., 1996, The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metabolism Reviews, 28, 345–472.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA, M., TANE, K., NAKAMURA, S., SHIMADA, N., YAMAZAKI, H. and YOKOI, T., 2002, Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using RAF effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. Journal of Pharmaceutical Sciences, 91, 952–963.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OBACH, R. S., 1999, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition, 27, 1350–1359.
   PubMed Web of Science ®Google Scholar
• ONG, C. E., COULTER, S., BIRKETT, D. J., BHASKER, C. R. and MINERS, J. 0., 2000, The xenobiotic inhibitor profile for cytochrome P4502C8. British Journal of Clinical Pharmacology, 50, 573–580.
   Google Scholar
• PROJEAN, D, Tu, T. M. and DUCHARME, J., 2003, A rapid and simple method to determine morphine and its metabolites in rat plasma by high-performance liquid chromatography coupled to mass spectrometry. Journal of Chromatography B, 787, 243–253.
   PubMed Web of Science ®Google Scholar
• RAHMAN, A., KORZEKWA, K. R., GROGAN, J., GONZALES, F. J. and HARRIS, J. W., 1994, Selective biotransformation of taxol to 6-alpha hydroxy taxol by human cytochrome P450 2C8. Cancer Research, 54, 5543–5546.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., 1999, Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical Pharmacology, 57, 465–480.
   PubMed Web of Science ®Google Scholar
• SCHMIDER, J., VON MOLTKE, L. L., SHADER, R. I., HARMATZ, J. S. and GREENBLATT, D. J., 1999, Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics, evaluation of the pharmacokinetic interaction between amitryptilline and fiuoxetine. Drug Metabolism Reviews, 31, 545–560.
   PubMed Web of Science ®Google Scholar
• SHEN, D. D., KUNZE, K. L. and THUMMEL, K. E., 1997, Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Advanced Drug Delivery Review, 27, 99–127.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SMITH, D. A. and JONES, B. C., 1992, Speculation on the substrate structure—activity relationship (SSAR) of cytochrome P450 enzymes. Biochemical Pharmacology, 44, 2089–2098.
   PubMed Web of Science ®Google Scholar
• Strömer, E., VON MOLTKE, L. L. and GREENBLATT, D. J., 2000b, Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance studies of mirtazapine metabolism Journal of Pharmacology and Experimental Therapeutics, 295, 793–801.
   Google Scholar
• Strömer, E., VON MOLTKE, L. L., SHADER, R. I. and GREENBLATT, D. J., 2000a, Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochrome P450 1A2, 2D6 and 3A4. Drug Metabolism and Disposition, 28, 1168–1175.
   Google Scholar
• TRACY, T. S., KORZEKWA, K. R., GONZALEZ, F. J. and WAINER, I. W., 1999, Cytochrome P450 enzymes involved metabolism of the enantiomers of verapamil and norverapamil. British Journal of Clinical Pharmacology, 58, 1201–1208.
   Google Scholar
• VENKATAKRISHNAN, K., VON MOLTKE, L. L. and GREENBLATT, D. J., 2001a, Application of the relative activity approach in scaling from heterologously expressed cytochrome P450 to human liver microsomes: studies on amitryptine as model substrate. Journal of Pharmacology and Experimental Therapeutics, 297, 326–337.
   PubMed Web of Science ®Google Scholar
• VENKATAKRISHNAN, K., Von MOLTKE, L. L. and GREENBLATT, D. J., 2001b, Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. Journal of Clinical Pharmacology, 41, 1149–1179.
   PubMed Web of Science ®Google Scholar
• WAXMAN, D. J., LAPENSON, D. P., AOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J. and KORZEKWA, K., 1991, Steroid hormone hydroxylase specificities for eleven cDNA-expressed human liver cytochrome P450s. Archives of Biochemistry and Biophysics, 290, 160–166.
   PubMed Web of Science ®Google Scholar
• WOOD, L. A., 1954, Distribution and fate of morphine in non tolerant and tolerant dogs and rats. Journal of Pharmacology and Experimental Therapeutics, 112, 158–175.
   PubMed Web of Science ®Google Scholar
• YEH, S. Y., GORODETZKY, C. W. and KREBS, H. A., 1977, Isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans. Journal of Pharmaceutical Sciences, 66, 1288–1293.
   PubMed Web of Science ®Google Scholar